Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Lenalidomide in myeloma--a high-maintenance friend.

Badros AZ.

N Engl J Med. 2012 May 10;366(19):1836-8. doi: 10.1056/NEJMe1202819. No abstract available.

PMID:
22571206
2.

Lenalidomide for multiple myeloma.

Bertolini F.

N Engl J Med. 2012 Aug 9;367(6):573; author reply 573-5. doi: 10.1056/NEJMc1206734#SA1. No abstract available.

PMID:
22873542
3.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
4.

[New treatment strategies for multiple myeloma].

Goldschmidt H, Nitschmann S.

Internist (Berl). 2013 Jul;54(7):892-6. doi: 10.1007/s00108-013-3299-3. German. No abstract available.

PMID:
23748490
5.

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.

Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, Kumar S, Rivera CE, Gertz MA, Buadi FK, Hayman SR, Rajkumar SV.

Blood Cancer J. 2015 Mar 20;5:e294. doi: 10.1038/bcj.2015.23. No abstract available.

6.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Islam A, Ambrus JL.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. doi: 10.1056/NEJMc086420. No abstract available.

7.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M.

J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.

PMID:
20940200
8.

Advances in therapy of multiple myeloma.

Bladé J, Rosiñol L.

Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Review.

PMID:
18841053
9.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20048187
10.

Drug interaction between lenalidomide and itraconazole.

Takahashi N, Miura M, Kameoka Y, Abumiya M, Sawada K.

Am J Hematol. 2012 Mar;87(3):338-9. doi: 10.1002/ajh.22260. Epub 2011 Dec 27. No abstract available.

11.

Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.

Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A.

Leukemia. 2013 Mar;27(3):695-701. doi: 10.1038/leu.2012.271. Epub 2012 Sep 21.

PMID:
22996335
12.

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network.

J Clin Oncol. 2007 Oct 1;25(28):4459-65. Epub 2007 Sep 4.

PMID:
17785703
13.

Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.

Jena RK, Swain TR, Kansurkar SS, Swain M.

Eur J Clin Pharmacol. 2012 May;68(5):881-4. doi: 10.1007/s00228-011-1152-y. Epub 2011 Nov 30.

PMID:
22127618
14.

Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.

Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A.

Eur J Haematol. 2010 Sep;85(3):200-8. doi: 10.1111/j.1600-0609.2010.01469.x. Epub 2010 May 8.

PMID:
20477865
15.

Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.

Moreau P, Hulin C, Facon T.

Hematol Oncol Clin North Am. 2014 Oct;28(5):829-38. doi: 10.1016/j.hoc.2014.06.002. Epub 2014 Jul 15. Review.

PMID:
25212885
16.

[Therapy of multiple myeloma: indications and options].

Peest D, Ganser A.

Internist (Berl). 2007 Dec;48(12):1343-8. Review. German.

PMID:
17960351
17.

Frontline regimens for multiple myeloma patients.

Lonial S.

Clin Adv Hematol Oncol. 2010 May;8(5):331-2. No abstract available.

PMID:
20551891
18.

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.

Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A.

Blood. 2011 Nov 24;118(22):5759-66. doi: 10.1182/blood-2011-05-353995. Epub 2011 Sep 27.

19.

Current treatment for multiple myeloma.

Avigan D, Rosenblatt J.

N Engl J Med. 2014 Sep 4;371(10):961-2. doi: 10.1056/NEJMe1407442. No abstract available.

PMID:
25184869
20.

Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.

White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman JA, Couban S.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):19-24. doi: 10.1016/j.clml.2012.08.009. Epub 2012 Nov 7.

PMID:
23141150

Supplemental Content

Support Center